169 related articles for article (PubMed ID: 7549905)
1. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.
Abraham RT; Acquarone M; Andersen A; Asensi A; Bellé R; Berger F; Bergounioux C; Brunn G; Buquet-Fagot C; Fagot D
Biol Cell; 1995; 83(2-3):105-20. PubMed ID: 7549905
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinases by purine analogues.
Veselý J; Havlicek L; Strnad M; Blow JJ; Donella-Deana A; Pinna L; Letham DS; Kato J; Detivaud L; Leclerc S
Eur J Biochem; 1994 Sep; 224(2):771-86. PubMed ID: 7925396
[TBL] [Abstract][Full Text] [Related]
4. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
5. Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions.
Glab N; Labidi B; Qin LX; Trehin C; Bergounioux C; Meijer L
FEBS Lett; 1994 Oct; 353(2):207-11. PubMed ID: 7523194
[TBL] [Abstract][Full Text] [Related]
6. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
[TBL] [Abstract][Full Text] [Related]
7. Cellular effects of olomoucine in human lymphoma cells differing in p53 function.
Fan S; Duba DE; O'Connor PM
Chemotherapy; 1999; 45(6):437-45. PubMed ID: 10567774
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of 6-DMAP, olomoucine and roscovitine on Xenopus oocytes and eggs.
Flament S; Bodart JF; Bertout M; Browaeys E; Rousseau A; Vilain JP
Zygote; 2000 Feb; 8(1):3-14. PubMed ID: 10840869
[TBL] [Abstract][Full Text] [Related]
10. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.
Havlícek L; Hanus J; Veselý J; Leclerc S; Meijer L; Shaw G; Strnad M
J Med Chem; 1997 Feb; 40(4):408-12. PubMed ID: 9046330
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
12. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines.
Buquet-Fagot C; Lallemand F; Montagne MN; Mester J
Anticancer Drugs; 1997 Jul; 8(6):623-31. PubMed ID: 9300578
[TBL] [Abstract][Full Text] [Related]
13. ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells.
Zhang W; Lee JC; Kumar S; Gowen M
J Bone Miner Res; 1999 Apr; 14(4):528-35. PubMed ID: 10234573
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
[TBL] [Abstract][Full Text] [Related]
15. Cdk2 activity is dispensable for the onset of DNA replication during the first mitotic cycles of the sea urchin early embryo.
Moreau JL; Marques F; Barakat A; Schatt P; Lozano JC; Peaucellier G; Picard A; Genevière AM
Dev Biol; 1998 Aug; 200(2):182-97. PubMed ID: 9705226
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
17. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
Iseki H; Ko TC; Xue XY; Seapan A; Townsend CM
J Gastrointest Surg; 1998; 2(1):36-43. PubMed ID: 9841966
[TBL] [Abstract][Full Text] [Related]
18. Meiotic cell cycle in Xenopus oocytes is independent of cdk2 kinase.
Furuno N; Ogawa Y; Iwashita J; Nakajo N; Sagata N
EMBO J; 1997 Jul; 16(13):3860-5. PubMed ID: 9233796
[TBL] [Abstract][Full Text] [Related]
19. Roscovitine, a novel cyclin-dependent kinase inhibitor, characterizes restriction point and G2/M transition in tobacco BY-2 cell suspension.
Planchais S; Glab N; Tréhin C; Perennes C; Bureau JM; Meijer L; Bergounioux C
Plant J; 1997 Jul; 12(1):191-202. PubMed ID: 9263460
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of the synthesis and activity of the major cyclin-dependent kinases, p34cdc2, p33cdk2, and p34cdk4, during cell cycle entry and progression in normal human T lymphocytes.
Lucas JJ; Szepesi A; Domenico J; Tordai A; Terada N; Gelfand EW
J Cell Physiol; 1995 Nov; 165(2):406-16. PubMed ID: 7593219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
